Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 60 Mg Daily Dose of Adefovir Dipivoxil in HIV-Infected Patients Naive to Anti-Retroviral Therapy

NCT00002206 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00002206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 60 Mg Daily Dose of Adefovir Dipivoxil in HIV-Infected Patients Naive to Anti-Retroviral Therapy
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
45
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections